Fig. 5. FimH promotes cancer antigen (Ag)-specific immune activation and anti-tumor immunity.

BALB/c mice were injected s.c. with 1 × 10⁶ CT26 carcinoma cells. After 7 and 14 days of tumor-cell injections, the mice were treated with PBS and 2.5 mg per kg of AH1A5, 2.5 mg per kg of FimH, or a combination of AH1A5 and FimH. The C57BL/6 mice were injected s.c. with 1 × 10⁶ B16 melanoma cells. After 7 and 14 days of tumor-cell injections, the mice received PBS and 2.5 mg per kg of TRP2, 2.5 mg per kg of FimH, or a combination of TRP2 and FimH. a The growth curves of the CT26 tumors in the BALB/c mice and b the B16 tumors in the C57BL/6 mice are shown. (n = 6 mice, significance determined by the log-rank test, mean ± SEM. c The CT26 carcinoma and d representative B16 melanoma tumor masses are shown. (n = 6 mice). e AH1A5-specific and f TRP2-specific IFN-γ production in the tumor drLN of the BALB/c and C57BL/6 mice are demonstrated, respectively. (n = 6 mice, one-way ANOVA, mean ± SEM).